End-of-day quote
Shanghai S.E.
23:00:00 16/05/2024 BST
|
5-day change
|
1st Jan Change
|
9.4
CNY
|
+0.11%
|
|
-2.89%
|
-37.91%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,636
|
8,706
|
5,421
|
-
|
-
|
Enterprise Value (EV)
1 |
7,636
|
8,706
|
5,421
|
5,421
|
5,421
|
P/E ratio
|
-14
x
|
-30.7
x
|
-18.8
x
|
-17.8
x
|
-78.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
46.9
x
|
42
x
|
16.9
x
|
12.1
x
|
EV / Revenue
|
-
|
46.9
x
|
42
x
|
16.9
x
|
12.1
x
|
EV / EBITDA
|
-
|
-31.8
x
|
-17.3
x
|
-27.1
x
|
-62.3
x
|
EV / FCF
|
-
|
-27.7
x
|
-22.9
x
|
-13.6
x
|
-20.5
x
|
FCF Yield
|
-
|
-3.61%
|
-4.38%
|
-7.33%
|
-4.89%
|
Price to Book
|
-
|
4.36
x
|
2.74
x
|
2.76
x
|
3.38
x
|
Nbr of stocks (in thousands)
|
575,000
|
575,000
|
576,659
|
-
|
-
|
Reference price
2 |
13.28
|
15.14
|
9.400
|
9.400
|
9.400
|
Announcement Date
|
27/02/23
|
06/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
185.5
|
129.2
|
320
|
447.5
|
EBITDA
1 |
-
|
-273.8
|
-314
|
-199.7
|
-87
|
EBIT
1 |
-
|
-284
|
-288
|
-186.9
|
-66
|
Operating Margin
|
-
|
-153.06%
|
-222.91%
|
-58.39%
|
-14.75%
|
Earnings before Tax (EBT)
1 |
-
|
-284
|
-288
|
-186.9
|
-67
|
Net income
1 |
-483.5
|
-284
|
-288
|
-183.4
|
-67
|
Net margin
|
-
|
-153.06%
|
-222.91%
|
-57.32%
|
-14.97%
|
EPS
2 |
-0.9500
|
-0.4939
|
-0.5000
|
-0.5267
|
-0.1200
|
Free Cash Flow
1 |
-
|
-314
|
-237.2
|
-397.1
|
-264.9
|
FCF margin
|
-
|
-169.27%
|
-183.59%
|
-124.1%
|
-59.2%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/02/23
|
06/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-314
|
-237
|
-397
|
-265
|
ROE (net income / shareholders' equity)
|
-
|
-13.5%
|
-21.2%
|
-12%
|
-4.2%
|
ROA (Net income/ Total Assets)
|
-
|
-13.3%
|
-15.3%
|
-12.9%
|
-3.5%
|
Assets
1 |
-
|
2,135
|
1,882
|
1,418
|
1,914
|
Book Value Per Share
2 |
-
|
3.470
|
3.440
|
3.400
|
2.780
|
Cash Flow per Share
2 |
-
|
-0.5400
|
-0.7400
|
-0.3200
|
-
|
Capex
1 |
-
|
6.29
|
9.3
|
13.2
|
60.3
|
Capex / Sales
|
-
|
3.39%
|
7.2%
|
4.11%
|
13.47%
|
Announcement Date
|
27/02/23
|
06/02/24
|
-
|
-
|
-
|
Average target price
18.5
CNY Spread / Average Target +96.81% Consensus |
1st Jan change
|
Capi.
|
---|
| -37.91% | 751M | | +9.42% | 115B | | +11.84% | 106B | | -2.65% | 21.96B | | -14.15% | 21.87B | | -5.29% | 19.21B | | -4.16% | 18.08B | | -38.29% | 17.71B | | +7.99% | 14.32B | | +36.24% | 12.42B |
Bio Therapeutic Drugs
|